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Cigarette smoke (CS) is the main cause of chronic obstructive pulmonary disease.
Surfactant protein D (SP-D) is an important anti-inflammatory protein that regulates
host immune defense in the lungs. Here, we investigated the role of SP-D in a
murine model of CS-induced inflammation. Pulmonary SP-D localization and abundance
was compared between smoker and non-smoker individuals. For in vivo studies,
wildtype, and SP-D-deficient mice were exposed to CS for either 12 weeks or 3
days. Moreover, the effect of therapeutic administration of recombinant fragment of
human SP-D on the acute CS-induced changes was evaluated. Pulmonary SP-D
appeared with heterogenous expression in human smokers, while mouse lung SP-D
was uniformly upregulated after CS exposure. We found that SP-D-deficient mice were
more susceptible to CS-induced macrophage-rich airway inflammation. SP-D deficiency
influenced local pro-inflammatory cytokine levels, with increased CCL3 and interleukin-6
but decreased CXCL1. Furthermore, CS exposure caused significant upregulation
of pro-inflammatory ceramides and related ceramide synthase gene transcripts in
SP-D-deficient mice compared to wildtype littermates. Administration of recombinant
fragment of human SP-D (rfhSP-D) alleviated CS-induced macrophage infiltration and
prevented induction of ceramide synthase gene expression. Finally, rfhSP-D treatment
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attenuated CS-induced human epithelial cell apoptosis in vitro. Our results indicate that
SP-D deficiency aggravates CS-induced lung inflammation partly through regulation of
ceramide synthesis and that local SP-D enrichment rescues CS-induced inflammation.
Keywords: surfactant protein D (SP-D), cigarette smoke (CS), mouse models, ceramide, ceramide synthase
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a serious
lung disease with increasing morbidity and mortality rates
worldwide (1). COPD is characterized by irreversible airflow
limitation caused by persistent inflammation and structural
changes (2). The major risk factor for COPD development and
progression is tobacco smoking (3). Experimental models have
shown that cigarette smoke (CS) exposure induces pulmonary
oxidative stress and local inflammation, mimicking many
characteristics of COPD (4). As existing therapeutic approaches
prove widely ineffective against CS-induced inflammation (5),
there is an urgent need for the development of new anti-
inflammatory treatments of COPD.
Surfactant protein D (SP-D) is a pulmonary collectin
produced by alveolar type II cells and club cells within the
respiratory tract. SP-D is an important innate immune molecule
that exerts its anti-inflammatory actions through multiple
mechanisms, such as direct antimicrobial activity, pathogen
opsonization, induction of phagocytic properties in alveolar
macrophages and regulation of soluble mediator production
from both structural and immune cells [reviewed in (6)]. In
mice, targeted SP-D ablation is reported to cause spontaneous
emphysema-like pathology (7). Lungs of SP-D-deficient mice
show disturbances in surfactant homeostasis and accumulation
of enlarged, foamy macrophages overproducing reactive oxygen
species and pro-inflammatory factors (7). Interestingly, SP-D
is upregulated by CS in murine airways, while it is decreased
in human bronchoalveolar lavage fluid (BAL) and increased in
serum of smokers and COPD patients (8–11). Moreover, single
nucleotide polymorphisms in the Stfpd gene encoding SP-D have
been associated with COPD in several independent cohorts (12),
suggesting the involvement of SP-D in regulation of CS-induced
pathology.
The exact role of SP-D in CS-induced inflammation remains
unknown. We hypothesized that SP-D regulates CS-induced
lung inflammation and that genetic ablation of SP-D leads to
aggravation of CS-induced pathology. To address this issue,
we subjected SP-D-deficient mice to subchronic and acute CS
exposure. Furthermore, recombinant fragment of human SP-
D (rfhSP-D) was administered to acutely exposed mice to
investigate whether local delivery of exogenous SP-D has a
potential to dampen CS-related inflammatory processes.
MATERIALS AND METHODS
SP-D Staining of Human Lung Tissue
Sections of non-malignant lung tissues collected from patients
undergoing pulmonary malignant tumor resection were
immunostained against SP-D (antibody produced in-house,
dilution 1:5,000) for 1 h and visualized with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody
and 3,3′-diaminobenzidine chromogen (both from Dako,
Glostrup, Denmark). Subject characteristics are shown
in Supplementary Table 1. The study was carried out in
accordance with the recommendations of the Regional Scientific
Ethics Committee for Southern Denmark with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
The protocol was approved by the Regional Scientific Ethics
Committee for Southern Denmark.
Animals
Male C57BL/6N wild type (WT) and SP-D-deficient littermate
mice (aged 8–10 weeks) (13) were used for all animal
experiments. Mice were housed in macrolon type II cages
containing aspen woodchip bedding (Tapvei, Brogaarden,
Gentofte, Denmark) and nesting material (EnviroDri,
Brogaarden, Gentofte, Denmark). The environment was
controlled with respect to temperature (21–24◦C) and
illumination (12 h light/dark cycle with a 30min sunset and
dawn function). The animals had access to pelleted chow and
water ad libitum. The Danish National Animal Ethics Committee
approved all animal experiments (ref. no. 2012-15-2934-00525
and 2016-15-0201-01077).
Genotyping
DNA was extracted from tail biopsies of 3-week-old mice
using the REDExtract-N-AmpTM Tissue PCR kit (Sigma-
Aldrich, St. Louis, MO, USA) according to the manufacturer’s
instructions. SP-D genotypes were identified by multiplex
PCR using the 5′-GGTTTCTGAGATGGGAGTCGTG-3′ as the
forward primer, and 5′-TGGGGCAGTGGATGGAGTGTGC-
3′ and 5′-GTGGATGTGGAATGTGCGAG-3′ as the reverse
primers recognizing the WT allele and the knockout allele,
respectively.
Recombinant Fragment of Human SP-D
(rfhSP-D)
RfhSP-D is a recombinant homotrimeric fragment of human
SP-D consisting of the carbohydrate recognition domain, alpha-
helical coiled-coil neck domain plus a short segment of 8
Gly-Xaa-Yaa repeats from the collagen domain. The fragment
was expressed and purified as previously described (14).
Endotoxin level in rfhSP-D was 1 EU/ml as measured by the
Limulus Amebocyte Lysate Assay (BioWhittaker, Lonza, Basel,
Switzerland).
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CS Exposure Procedure and rfhSP-D
Administration
A whole body CS exposure system was used and consisted of
a time-set pinch valve (C Lee Machining, Horsham, UK), an
exposure chamber (Teague Enterprises, CA, USA) and a total
suspended particulate (TSP) sampling unit (Teague Enterprises).
Mice were exposed to mainstream CS five consecutive days a
week for 12 weeks (subchronic protocol) or for 3 consecutive days
(acute protocol) using 3R4F cigarettes without filter (Tobacco
Health Research Institute, University of Kentucky, Lexington,
KY, USA). CS was generated using a negative pressure system
(flow-rate set at 1,500 ml/min). Room air was continuously
pumped into the chamber for the remaining period between
puffs. Mice were subjected to two consecutive rounds of smoking
lasting 50min each, with a smoke-free interval of 30min between
exposures. TSP levels were monitored by sampling a known
air volume from the chamber through a filter (Pallflex Air
Monitoring Filters TX40HI20-WW, Life Sciences, Pall, Port
Washington, NY, USA) to validate CS consistency within the
chamber. The average TSP concentration in the chamber was
457 mg/m3. Blood samples from facial vein were collected
every 4th week, and serum cotinine levels were assessed by
ELISA (Calbiotech, Spring Valley, CA, USA) according to the
manufacturer’s instructions. Control, room air-exposed mice
were housed together with CS-exposed mice except for the
smoking periods and underwent the same anesthetic procedures.
In some acutely treated mice, rfhSP-D (15 µg in 50 µl PBS)
was administered intranasally under light isoflurane anesthesia
1 h prior to each smoking period (Supplementary Figure 1).
Control mice received intranasal PBS only.
Lung Function Measurements
Twenty-four hour after the last exposure mice were anesthetized
by intraperitoneal injection of ketamine (100 mg/kg) and
xylazine (10 mg/kg), tracheostomized and connected to a
computer-controlled small animal ventilator (Flexivent, SCIREQ,
Montreal, Canada). Lung function parameters were measured
with mechanical ventilation set at 150 breaths/min with a tidal
volume of 10 ml/kg and a positive end-expiratory pressure of
3 cm H2O. For each parameter, a coefficient of determination of
0.95 was the lower limit for accepting a measurement.
Immediately after lung function testing the mice were
sacrificed by cardiac puncture. Serum was isolated by
centrifugation (3,000 g, 5min) from coagulated blood.
BAL Preparation
The lungs were lavaged four times with 0.5ml ice-cold
phosphate-buffered saline (PBS) without Ca2+ andMg2+ (Gibco,
Waltham, MA, USA). PBS was instilled into the lungs and
allowed to equilibrate for at least 30 s before recovery. The four
aliquots were pooled and centrifuged at 900 g for 10min at
4◦C, and the supernatants were stored at −80◦C until further
analysis. Cells were washed in Red Blood Cell Lysing Buffer
Hybri-Max (Sigma) and resuspended in PBS. Total cell number
was determined with a Z2 Beckman-Coulter particle counter.
Afterwards cells were cytospun at 500 rpm for 5min and
stained with Hemacolor (Merck Millipore, Billerica, MA, USA).
Differential cell count was performed in a blinded manner by
two independent observers, with 200 counted cells/sample. Mean
macrophage diameter was calculated in a blinded manner by
measuring cell diameter from at least three random fields of
vision/section using ImageJ software (15).
Measurements of Endogenous SP-D and
rfhSP-D in BAL
Endogenous SP-D and rfhSP-D levels in BAL were quantified by
ELISA as previously described (16).
Flow Cytometry Analysis of BAL Cell
Apoptosis
Isolated BAL cells were stained with Dead Cell Apoptosis
Kit (Thermo Fisher Scientific), containing annexin V-FITC
and propidium iodide (PI), according to the manufacturer’s
instructions. Apoptotic cells were defined as annexin V-positive,
PI-negative.
Cytokine Measurements
A Bio-Plex mouse cytokine and chemokine panel (Bio-Rad,
Copenhagen, Denmark) was used to quantify CCL2, CCL3, IL-
1β, IFN-γ, and TNF in BAL after 12 weeks of CS exposure.
The assay was performed according to the manufacturer’s
instructions. The analysis was performed with a Luminex 100 IS
2.3 system using the Bio-Plex Manager 4.1.1 software.
The levels of CCL2, CCL3, IL-1β, IL-6, IFN-γ, TNF, and KC in
BALweremeasured using commercial ELISA kits (R&D Systems,
Minneapolis, MN, USA, and eBioscience, San Diego, CA, USA)
according to the manufacturers’ instructions.
RNA Extraction and cDNA Synthesis
The lungs were snap-frozen in liquid nitrogen and stored in
−80◦C until further processing. Lung RNA was isolated using
TRIzol reagent according to the manufacturer’s instructions
(Invitrogen). cDNA was synthesized using the QuantiTect
Reverse Transcription Kit (Qiagen, Denmark) according to the
manufacturer’s introductions.
Real-Time PCR
Real-time PCR (qPCR) was performed using Taqman Universal
PCR Master Mix II and Taqman Gene Expression Assays
(Applied Biosystems, Carlsbad, CA, USA) for the following
genes: Sftpd (Mm00486060), Tbp (Mm00446971), Gapdh
(Mm99999915), Cers2 (Mm01258345), CerS5 (Mm00510998),
CerS6 (Mm00556165). Reactions were performed in duplicates
on a StepOnePlus Real-Time PCR system. Relative mRNA levels
were calculated using the 211CT method. Tbp and Gapdh were
used as endogenous controls.
Lipid Analysis
Lipid analysis was performed at the Analytical Facility for
Bioactive Molecules (The Hospital for Sick Children, Toronto,
Canada). Samples were spiked with a mixture of internal
standards (IS) (C17 base ceramide (10 ng) and PC, LPC (1
µg)). BAL samples (200 µl) and standards were extracted twice
with 2:1 chloroform:methanol mixture. The lower chloroform
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FIGURE 1 | Regulation of pulmonary SP-D levels by cigarette smoke (CS) in humans and mice. (A) Human SP-D is upregulated in the lungs of smokers compared to
non-smoker controls. Each picture represents a single subject. Examples of alveolar type II cells and alveolar macrophages are marked with red arrows
and arrowheads, respectively. Representative pictures are shown. Scale bar, 100µm. (B,C) Endogenous murine SP-D is upregulated in bronchoalveolar lavage fluid
(BAL) after (B) 12 weeks and (C) 3 days of CS exposure. n = 5–7. *p < 0.05, analyzed by Student’s t-test.
layers were removed, combined, and then taken to dryness
under a gentle flow of nitrogen gas. Residues were reconstituted
in 100 µl 0.2% formic acid in ethanol and analyzed by LC-
MS/MS. LC/MS/MS HPLC was performed using an Agilent 1200
Series HPLC (Agilent, Santa Clara, CA, USA). The analytical
column was Kinetex C18 (100 × 2.1mm, 2.6µm particle
size) from Phenomenex (Phenomenex, Torrance, CA). The
HPLC mobile phases consisted of (A) = 0.05% formic acid
in water/acetonitrile/methanol (2/1/1, v/v/v) and (B) = 0.05%
formic acid in tetrahydrofuran/acetonitrile/methanol (2/1/1,
v/v/v). A flow rate of 0.4 ml/minute was used with a gradient of
solvent composition 40%B to 85%B, followed by re-equilibration
to initial condition for 2min. Each run lasted 19min. The HPLC
system was coupled to an AB SCIEX API4000 triple-quadrupole
mass spectrometry (SCIEX, Framingham, MA, USA). Positive
electro spray ionization (ESI) multiple reaction monitoring
(MRM)was used. Data were collected and analyzed using Analyst
v.1.5.1 (SCIEX).
Western Blotting
Frozen lung tissues were homogenized in RIPA buffer (Sigma)
containing protease inhibitors (Complete tablets, Roche,
Indianapolis, IN, USA). Samples were equalized according to
the protein concentration, boiled for 1min in 4x loading buffer,
separated by SDS-PAGE on NuPage 4–12% Bis-Tris gels (Bio-
rad, Hercules, CA, USA) and transferred onto polyvinylidene
fluoride membranes using the semidry transfer system (Bio-rad).
The membranes were then blocked for 2 h at room temperature
with 5% nonfat dry milk (Bio-rad) in Tris-buffered containing
0.5M NaCl and 0.1% Tween (TBST), incubated with primary
antibodies against GAPDH (1:500, Santa Cruz) or LC3B (1:5000,
Sigma) overnight at 4◦C, washed with TBST and incubated with
goat anti-rabbit Ig-HRP or rabbit anti-mouse Ig-HRP secondary
antibody (1:5000 and 1:10000, respectively, both from Dako,
Glostrup, Denmark). Protein expression was detected using ECL
reagents and quantified by densitometry using Image Studio Lite
software (LI-COR Biotechnology).
Cigarette Smoke Extract (CSE) Preparation
CSE was prepared by bubbling smoke from one 3R4F research
cigarette without filter into a Buchner flask containing 10ml
of RPMI-1640 medium (Thermo Fisher Scientific, Waltham,
MA, USA). The smoke was drawn into the medium under
vacuum over a period of 1–2min. CSE was then filtered through
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0.22µm filter (GE Healthcare, Broendby, Denmark) and used
immediately. Medium bubbled with room air was used as a
control.
Apoptosis Assay
Human adenocarcinoma alveolar basal epithelial A549
epithelial cells (ATCC) were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum, 2mM L-glutamine,
50 U/ml penicillin and 50µg/ml streptomycin (all from
Gibco). Cells were seeded in 96-well plates at the density
of 10,000 cells/well. After 8 h of incubation allowing for the
attachment, cells were serum-starved overnight and stimulated
with 2.5% CSE for 24 h. In some experiments, cells were pre-
treated with 20µg/ml rfhSP-D 1 h before and throughout CSE
stimulation. Cell apoptosis was assessed by Caspase-Glo R©3/7
Assay (Promega) according to the manufacturer’s instructions.
Statistical Analysis
Statistical analysis was performed using Prism 7 software
(GraphPad, La Jolla, California, USA). Data are presented as
means + SEM. Parametric results were analyzed using Student’s
t-test or one-way analysis of variance (ANOVA) followed
by Bonferroni’s multiple comparisons test. Correlations were
analyzed with Pearson’s test. A p < 0.05 was considered
statistically significant.
RESULTS
Endogenous SP-D Is Upregulated by CS
Initially, we analyzed the SP-D staining pattern in human
lung tissue. In the lungs of non-smokers, SP-D was localized
to alveolar type II cells and weakly to alveolar macrophages.
By contrast, lungs from smokers exhibited focal areas rich in
alveolar type II cells strongly positive for SP-D (Figure 1A),
while areas with marked tissue loss appeared with low SP-D
expression similar to that of non-smoker lungs (not shown).
Alveolar macrophages from smokers appeared with more intense
immunostaining for SP-D than from non-smoking individuals
(Figure 1A).
We then analyzed possible CS-dependent regulation of
SP-D expression in mice. Similar to previous findings (8),
endogenous SP-D levels were elevated in BAL of WT mice
exposed to CS for 12 weeks or 3 days (Figures 1B,C). We
did not detect SP-D upregulation by CS on the mRNA level
(Supplementary Figure 2). Mean serum cotinine levels were
comparable between CS-exposed WT and SP-D-deficient mice
(207.7 ± 32.3 ng/ml and 154.9 ± 43 ng/ml, respectively) and
remained undetectable in control animals.
SP-D Deficiency Causes Alterations in
Lung Mechanics Similar to CS-Induced
Changes
We performed invasive lung function testing to assess
potential aggravating effects of prolonged CS exposure on
mechanical properties of SP-D-deficient lungs. Subchronic CS
exposure had only minor effects on lung function parameters
(Supplementary Figure 3), possibly because the experimental
FIGURE 2 | SP-D deficiency and cigarette smoke (CS) exposure cause
changes in pulmonary mechanics in mice. Changes in lung hysteresivity after
12 weeks of CS exposure. n = 6–8. *p < 0.05, **p < 0.01, analyzed by
one-way ANOVA followed by Bonferroni’s test.
protocol was too short when using the C57BL/6 strain that is
only mildly susceptible to CS-induced emphysema (4). Both
inspiratory capacity and the estimate for total lung capacity
were significantly increased by CS exposure in both genotypes
(Supplementary Figures 3G,H). Interestingly, we also found
that lung hysteresivity was increased in naïve SP-D-deficient
mice to the level seen in CS-exposed WT mice, and was
not increased further after CS (Figure 2). Hysteresivity is
defined as a ratio between tissue damping and tissue elastance
(Supplementary Figures 3D,E), parameters describing energy
dissipation and energy conservation in the alveoli, respectively.
Increased lung hysteresivity reflects pulmonary structural and
functional abnormalities (17), which indicates that air space
enlargement induced by SP-D deficiency causes disruption of the
viscoelastic mechanical balance of the lungs.
SP-D Deficiency Aggravates Airway
Macrophage Inflammation Caused by CS
Mice exposed to CS for 12 weeks displayed higher total number
of BAL cells, specifically macrophages and neutrophils. The
increase in macrophage number was significantly higher in
SP-D-deficient mice than in WT littermates (Figures 3A–C).
We observed similar inflammatory pattern in the airways of
acutely smoked mice, where CS exposure for 3 days caused
the increase in BAL neutrophil and macrophage numbers, the
latter being significantly higher in SP-D-deficient mice compared
to WT littermates (Figures 3D–F). As expected, naïve SP-D-
deficient mice exposed to room air had higher number of BAL
macrophages than age-matched WT mice.
Treatment With RfhSP-D Ameliorates
Acute CS-Induced Airway Macrophage
Inflammation
We then investigated if administration of rfhSP-D could rescue
the inflammatory phenotype of SP-D-deficient mice seen after
3 days of CS exposure. Both total cell count and macrophage
numbers in BAL were significantly attenuated in mice treated
with rfhSP-D, while the number of neutrophils remained
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FIGURE 3 | SP-D deficiency aggravates cigarette smoke (CS)-induced airway inflammation in mice. SP-D-deficient mice exhibit higher total cell count and
macrophage number in bronchoalveolar lavage fluid (BAL) compared to WT littermates both after (A,B) 12 weeks and (D,E) 3 days of CS exposure, while the increase
in neutrophil numbers induced by (C) 12 weeks, or (F) 3 days of CS exposure is not influenced by SP-D deficiency. n = 5–7 (A–C), 7–12 (D–F). *p < 0.05, ** p <
0.01,*** p < 0.001, **** p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test. ns, not significant.
unaffected (Figures 4A,B and data not shown). Moreover, rfhSP-
D administration to CS-exposed mice resulted in normalization
of BAL macrophage size (Figure 4C). Importantly, rfhSP-D
reduced local macrophage inflammation in all experimental
groups (Figures 4A,B). Administration of rfhSP-D had no effect
on endogenous SP-D secretion (data not shown).
Regulation of Pulmonary Pro-Inflammatory
Mediators After CS Exposure
To determine if modulation of cytokine levels could explain
the differences observed in inflammatory cell content, we
investigated the airway cytokine profile of CS-exposed mice.
We did not observe changes in BAL levels of interleukin
(IL)-1β, interferon (IFN)-γ and tumor necrosis factor (TNF)
between groups exposed to CS for 12 weeks (data not shown),
while CCL2 was increased independently of SP-D genotype
(Supplementary Table 2). However, CS-treated SP-D-deficient
mice showed significantly elevated BAL levels of macrophage
chemoattractant CCL3 compared toWT littermates (Figure 5A).
Moreover, CCL3 levels in CS-exposed SP-D-deficient mice were
significantly correlated with BAL cell count, suggesting its role in
macrophage attraction to the SP-D-deficient lung (Figure 5B).
Acute CS exposure did not influence IL-1β, IFN-γ, or
TNF levels (data not shown), while CCL2 and CCL3 were
only modestly increased independent of SP-D genotype
(Supplementary Table 2). However, we detected significant
differences in regulation of CXCL1, which was upregulated
after CS in WT but not in SP-D-deficient mice (Figure 5C).
Furthermore, BAL levels of IL-6 were significantly higher in
SP-D-deficient mice than WT littermates following acute CS
exposure (Figure 5D).
CS Induces Upregulation of Ceramides as
Well as Ceramide Synthase (CerS) Genes
in SP-D-Deficient Mice That Is Reversed by
RfhSP-D
Next, we used mass spectrometry (MS) to analyze the
lipid profile in BAL of CS-exposed mice. As expected, SP-
D-deficient mice showed elevated BAL phospholipid pool
(Supplementary Table 3). The levels of analyzed phospholipids
were not influenced by CS exposure (Supplementary Table 3).
Furthermore, we observed significant differences in pro-
inflammatory long-chain and very long-chain ceramides, which
were upregulated by CS but, importantly, also by SP-D deficiency
(Figures 6A–C). These changes were detectable already after 3
days of CS exposure (Figures 6D–F). Levels of corresponding
dihydroceramide species were also the highest in CS-exposed
SP-D-deficient mice (Supplementary Figure 4).
To follow up on these observations, we investigated the
expression pattern of genes responsible for ceramide synthesis.
We observed that CS exposure induced upregulation of CerS2
and CerS5 in SP-D-deficient mice but not in WT littermates
(Figures 7A,B). Moreover, administration of rfhSP-D was able
to normalize the expression of CerS2 and CerS5 to control levels
(Figures 7A,B) as well as downregulate the related enzyme CerS6
(Figure 7C).
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FIGURE 4 | Therapeutic administration of recombinant SP-D fragment attenuates airway inflammation caused by acute cigarette smoke (CS) exposure in mice.
Treatment with recombinant fragment of human SP-D (rfhSP-D) lowers (A) total cell number, (B) macrophage number, and (C) macrophage size in bronchoalveolar
lavage fluid (BAL) of CS-exposed mice. n = 4–8. *p < 0.05, **p < 0.01, ***p < 0.001, analyzed by one-way ANOVA followed by Bonferroni’s test.
FIGURE 5 | SP-D-dependent regulation of cigarette smoke (CS)-induced pro-inflammatory cytokines in mice. (A) CCL3 levels in bronchoalveolar lavage fluid (BAL) are
significantly increased in SP-D-deficient mice compared to WT littermates after subchronic CS exposure. (B) Significant correlation between BAL levels of CCL3 and
total BAL cell count in CS-exposed SP-D-deficient mice. (C) SP-D-deficient mice fail to upregulate CXCL1 in BAL after acute CS exposure. (D) BAL levels of IL-6 after
acute CS exposure. n = 5–13. *p < 0.05, **p < 0.01, ****p < 0.0001, analyzed by (A,C) one-way ANOVA followed by Bonferroni’s test or (D) Student’s t-test.
Effect of SP-D Deficiency and RfhSP-D on
CS-Induced Cell Death
As CS and subsequent ceramide accumulation may lead to
alveolar cell death through various pathways, such as autophagy
and apoptosis (18), we investigated if SP-D genotype influences
these processes. SP-D-deficient mice subjected to subchronic CS
exposure showed increased autophagy, detected as increase in
abundance of lipidated, active form of the crucial autophagy
protein LC3B (LC3B-II) within the lung, compared to CS-
exposed WT littermates (Figures 8A,B).
Finally, we co-stimulated human alveolar epithelial A549 cells
with CSE and rfhSP-D to investigate if exogenous SP-D can be
protective against CSE-triggered toxicity. CSE induced caspase-
dependent apoptosis in A549 cells at low concentrations and was
highly cytotoxic at concentrations above 5% (data not shown).
Administration of rfhSP-D attenuated apoptosis measured
as caspase-3/7 activation caused by 2.5% CSE stimulation
(Figure 8C).
DISCUSSION
In this study, we evaluated the role of SP-D in the development of
CS-induced inflammation. We showed that SP-D appeared with
focally increased expression in CS-exposed human lungs. We
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FIGURE 6 | Upregulation of pulmonary ceramides in cigarette smoke (CS)-exposed SP-D-deficient mice. SP-D-deficient mice show higher levels of long-chain and
very long-chain ceramides in bronchoalveolar lavage fluid (BAL) after (A–C) 12 weeks and (D–F) 3 days of CS exposure compared to WT littermates. n = 4–7. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, analyzed by one-way ANOVA followed by Bonferroni’s test.
FIGURE 7 | Recombinant SP-D administration reverses pulmonary overexpression of ceramide synthases (CerS) in cigarette smoke (CS)-exposed mice. Lung mRNA
levels of (A) CerS2, (B) CerS5, and (C) CerS6 are increased after acute CS exposure in SP-D-deficient mice and are normalized by treatment with recombinant
fragment of human SP-D (rfhSP-D). n = 5–14. *p < 0.05, **p < 0.01, ***p < 0.001, analyzed by one-way ANOVA followed by Bonferroni’s test.
further demonstrated that SP-D-deficient mice are susceptible
to macrophage-rich airway inflammation and pro-inflammatory
ceramide accumulation caused by CS exposure, and that rfhSP-
D treatment reverses macrophage accumulation as well as
upregulation of CerS genes that are crucial for ceramide
generation. Finally, we also showed that SP-D-deficient mice
exhibit elevated pulmonary levels of autophagy markers after
prolonged CS exposure and that rfhSP-D attenuates CSE-induced
epithelial cell apoptosis in vitro. Collectively, our results describe
SP-D as an important regulator of CS-induced pulmonary
inflammation.
Both local and circulatory SP-D levels are disturbed in
smokers and COPDpatients, who exhibit vast induction of serum
SP-D with a concomitant reduction of BAL SP-D (9, 19). This
has been attributed to increased leakage of pulmonary SP-D
from the alveolar space into blood (20). High serum SP-D has
been linked to increased COPD mortality (21). It has also been
shown to inversely correlate with lung function parameters (19)
and its levels further rise during COPD exacerbations, possibly
reflecting local compensatory upregulation of pulmonary SP-
D (22) or further exaggerated alveolar-capillary leakage. Here
we show that SP-D is focally upregulated in the alveolar
epithelium andmacrophages of smokers, most probably as a local
compensatory mechanism aimed for cellular protection against
CS-induced damage. This response seems heterogenous across
the lung parenchyma, as areas of low tissue density showed
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FIGURE 8 | The effect of endogenous and exogenous SP-D on
cigarette smoke (CS)-induced human epithelial cell death. (A,B) Autophagy
marker LC3B-II (lower band) is increased in lung homogenates of
SP-D-deficient mice after 12 weeks of CS exposure. Each lane in (A)
represents a single lung homogenate sample, and the relative band density is
quantified in (B). (C) In vitro administration of recombinant fragment of human
SP-D (rfhSP-D) attenuates cigarette smoke extract (CSE)-induced apoptosis of
A549 alveolar epithelial cells. The cells were pre-treated with 20µg/ml rfhSP-D
for 1 h before stimulation with 2.5% CSE for 24 h. Apoptosis was measured as
relative caspase-3/7 activity. Data are means of 5 independent experiments. *p
< 0.05, analyzed by one-way ANOVA followed by Bonferroni’s test.
SP-D expression levels similar to that observed in non-smoker
lungs.
Contrary to the clinical situation described above, endogenous
murine SP-D levels were elevated in BAL after both subchronic
and acute CS exposure, which is in agreement with a previous
study of chronic, 6-months-long CS challenge (8). As SP-D is
also upregulated in BAL in other disease models, such as LPS- or
bleomycin-induced inflammation, such compensatory increase
in pulmonary SP-D seems as a common sign of lung injury
in the mouse (23). Although we have not detected previously
reported changes in SP-D mRNA expression after CS exposure
(8), differences in mouse strain (previously used B6C3F1 mice
are extremely sensitive to CS exposure), type of cigarettes and
exposure time might explain why the CS-related effects on SP-D
mRNA levels were more pronounced in the previous study.
Effects of CS exposure in mice are highly strain-dependent.
BALB/c mice are susceptible to CS-induced pathology
characterized by potent neutrophil recruitment and cytokine
upregulation, while CS exposure of relatively resistant C57BL/6
strain results in macrophage-rich infiltration and a limited
increase of pro-inflammatory mediators (4, 24). Accordingly,
we detected only minor changes in BAL pro-inflammatory
cytokine profile after CS exposure. Nevertheless, levels of CCL3
and IL-6 were significantly increased due to SP-D deficiency.
CCL3 is a potent monocyte and macrophage chemoattractant
(25) that is increased in sputum of COPD subjects (26). We
showed that BAL CCL3 levels are elevated in SP-D-deficient
mice and positively correlate with the airway inflammatory
cell number, which underlines its importance in CS-induced
mononuclear cell recruitment to the SP-D-deficient lung. IL-6
is a pro-inflammatory cytokine implicated in the pathogenesis
of COPD (27, 28) and previously reported to be upregulated in
SP-D-deficient mice (29). Interestingly, IL-6 seems to regulate
CCL3 expression after pulmonary insult (30). We suggest
that increased CCL3 is responsible for macrophage influx
to the airways in SP-D-deficient mice, possibly through an
IL-6-dependent mechanism that remains to be elucidated.
Unexpectedly, we observed that CS-exposed SP-D-deficient
mice failed to upregulate CXCL1, a canonical neutrophil
chemoattractant. In line with our findings, absence of CXCL1
upregulation has also been recently reported in SP-A/SP-
D double-deficient mice subjected to urinary tract infection
(31). Apart from its anti-inflammatory functions mediated
by the recognition of the C-terminal domain, full-length SP-
D is also capable of mounting pro-inflammatory responses
through interaction between its N-terminal collagenous tail and
calreticulin/CD91 receptor complex (32), which might explain
why CXCL1 is not generated after CS in SP-D-deficient mice.
However, presence of CXCL1 was not critical for pulmonary
neutrophil recruitment in our study, as BAL neutrophil numbers
were similar in CS-exposed WT and SP-D-deficient mice.
SP-D deficiency causes excessive accumulation of surfactant
phospholipids (33). We performed detailed MS-based analysis
and showed that CS exposure has no impact on BAL
phospholipid pool. However, we observed that ceramides,
particularly the most abundant long- and very long-chain
species (16:0), (24:0) and (24:1), respectively, are upregulated
in SP-D-deficient mice. Thus, we are, to our best knowledge,
the first to report SP-D involvement in ceramide biology.
Ceramides are bioactive sphingolipids with pro-inflammatory
and pro-apoptotic properties that are increased by CS exposure
in vivo, leading to alveolar and endothelial cell death and
subsequently emphysema (34, 35). Ceramide can be generated
by three distinct pathways: de novo formation, salvage from
sphingosine or sphingomyelinase-dependent sphingomyelin
cleavage [reviewed in (36)]. We also detected increases in
corresponding dihydroceramide species that are direct ceramide
precursors in the de novo pathway, which suggests de novo
synthesis as a potential mechanism of ceramide upregulation in
CS-exposed SP-D-deficient mice.
The family of CerS enzymes, responsible for the crucial
step of de novo ceramide synthesis, contains six members with
distinct substrate specificity. CerS2 uses C22-C24 fatty acyl
chains, while CerS5/CerS6 use mostly C16 to generate very
long-chain and long-chain ceramides, respectively; these are
also the most abundant pulmonary CerS isoforms (37). The
balance between ceramide species is crucial for maintaining
lung homeostasis, underlined by the phenotype of CerS2-null
mice that show accumulation of foamy alveolar macrophages
and increase in total lung volume, possibly caused by strong
compensatory accumulation of C16-ceramide (37). Both C16-
and C24-ceramides have been implicated in pro-apoptotic
signaling, leading to caspase-3 activation (38, 39). We showed
that SP-D deficiency renders lungs susceptible to CS-induced
upregulation of relevant CerS that can be reversed by rfhSP-
D. SP-D-mediated inhibition of p38-induced stress response
(32) is likely responsible for this effect. However, this was not
explored further, and future studies are needed to clarify the exact
mechanisms behind rfhSP-D regulation of ceramide synthesis.
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Besides apoptosis, other types of cell death including
autophagy have been recently linked to CS-induced lung injury
and COPD pathogenesis (40), and long chain ceramides have
been shown to mediate this response (41). We have found
that SP-D deficiency aggravates the increase in active autophagy
protein after prolonged CS exposure, further strengthening the
hypothesis that SP-D participates in controlling CS-induced
pathology through regulation of ceramides and their downstream
effects on cellular stress.
As the 3-months-long subchronic CS exposure was not
sufficient to induce a marked loss of alveolar tissue in SP-D-
deficient mice, we did not pursue investigation of epithelial
apoptosis in vivo. Instead, such effects were investigated in
human epithelial cells in vitro. We found that rfhSP-D attenuated
effector caspase activation in A549 cells exposed to low dose
CSE. This implicates that SP-D protects epithelial cells fromCSE-
induced apoptosis. Ceramide accumulation has been previously
reported to be responsible for caspase-dependent apoptosis in
lung epithelial cells (42). Thus, SP-D-dependent downregulation
of ceramide generation might be responsible for the observed
epithelial protection from apoptosis in cells treated with rfhSP-
D. Of note, protective effects of murine SP-D overexpression on
CS condensate-induced toxicity have been previously reported
in A549 cells (8) and SP-D has been shown to inhibit caspase-
3 activation (43, 44). On the other hand, SP-D-mediated effects
on apoptosis seem to be context-specific, with recent reports
indicating that SP-D can actually induce apoptosis in cancer
cell lines (45–47). The possible mechanistic link between SP-D-
induced ceramide inhibition and alveolar epithelium protection
remains to be investigated in further details.
Immunomodulatory functions of SP-D have been highlighted
by several therapy-based animal studies that used local
installation of exogenous SP-D. Full-length human SP-D
administration protected against ventilation-induced lung injury
and inflammation in premature newborn lambs (48), while
rfhSP-D has been reported to attenuate allergic asthma (49).
In agreement with this, we showed that rfhSP-D treatment
attenuates CS-induced macrophage infiltration, emphasizing its
protective potential. Importantly, the protective effects of rfhSP-
D were also present in WT mice, which suggests that although
we observed upregulation of endogenous SP-D in WT mice, this
compensatory increase in SP-D production is itself not sufficient
to control CS-induced inflammation. Compared to native SP-
D, rfhSP-D contains only a small collagen chain, a coiled-coil
region and a carbohydrate recognition domain. Despite lacking
the collagenous tail, rfhSP-D seems fully capable of mounting
anti-inflammatory responses, previously suggested to be a
consequence of the binding between its C-terminal carbohydrate
recognition domain and SIRP-α receptor on resident cells,
leading to inhibition of NF-κB signaling (32). Importantly,
increased endogenous SP-D levels have been recently shown to
confer protection against COPD risk and lung function decline,
which supports SP-D as a very promising therapeutic target (50)
and warrants further studies on SP-D-based therapy.
A limitation of our study is that we used a single rfhSP-D
concentration. However, more detailed dose response analysis
would help to establish the optimal conditions of rfhSP-D
treatment. Furthermore, the CS exposure model mimics the
inflammatory component of COPD only to a limited extent and
may only reflect early events in CS-induced pulmonary injury
seen in humans, before a significant loss of alveolar tissue occurs.
As our SP-D-deficient mice were on the C57BL/6 background
that is relatively resistant to CS-induced emphysema, a much
longer CS exposure than the used 3-months-long subchronic
model would be necessary to provoke significant changes in
pulmonary architecture.
In conclusion, we have shown that SP-D deficiency
aggravates airway macrophage inflammation and ceramide
accumulation caused by CS exposure, and that local rfhSP-
D administration attenuates CS-induced inflammation and
ceramide synthesis as well as epithelial cell apoptosis. Thus,
we have identified a possible novel mechanism by which
SP-D protects against pulmonary pathology triggered by CS
exposure.
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